Britain’s next research choice
Science · 18.06.2026 · 392 (6804) · 1217-1217
DOI: 10.1126/science.aej6498 ↗Kurz gefasst
Editorial in der Zeitschrift Science, erschienen am 18.06.2026. Verfasst von Ben Johnson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ben Johnson is a professor in the Department of Research and Innovation Policy, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: Biomedical Research, Research.
Abstract (Originalsprache)
Ten years ago, the Brexit referendum began the United Kingdom’s departure from the European Union (EU), forcing British science to confront a serious question: What place should the UK occupy in European research? No longer qualified to be a full-fledged member of Horizon Europe, the matter of whether to rejoin as an associate member became a totemic issue for the UK. There were serious questions around whether rejoining would be worth the money, especially if it had to pay in more funding than it could win back in grants. UK researchers, however, insisted that association was the best way to protect their access to the most prestigious and attractive funding opportunities. So, when the UK eventually associated in 2024, it was to sighs of relief. But times have changed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Ben Johnson is a professor in the Department of Research and Innovation Policy, University of Strathclyde, Glasgow, UK.
- Will Stone is a researcher at Science Works, London, UK.
Zitieren
APA
Johnson, B., & Stone, W. (2026). Britain’s next research choice. Science, 392(6804), 1217-1217. https://doi.org/10.1126/science.aej6498
Vancouver
Johnson B, Stone W. Britain’s next research choice. Science. 2026;392(6804):1217-1217. doi:10.1126/science.aej6498
BibTeX
@article{Johnson2026,
author = {Johnson, Ben and Stone, Will},
title = {Britain’s next research choice},
journal = {Science},
year = {2026},
volume = {392},
number = {6804},
pages = {1217--1217},
doi = {10.1126/science.aej6498}
}
EUVIMED